Global Melanoma Drugs Market

Melanoma Drugs Comprehensive Study by Application (Hospitals, Clinics, Other), Therapy (Chemotherapy, Immuno-therapy, Targeted Therapy, Radiation Therapy) Players and Region - Global Market Outlook to 2030

Melanoma Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Melanoma Drugs
Melanoma is a type of skin cancer that occurs due to major risk factor like high levels of exposure to ultraviolet (UV) light leading to blistering sunburns, particularly among population groups who stay either in countries, which are in proximity to the equator or at very high altitudes. According to the American Academy of Dermatology, the prevalence of melanoma is gradually increasing & rapidly spreads to other parts of the body. Nevertheless, if melanoma is detected at an early stage i.e. in situ or stage 0, it can be cured completely with surgical removal without any delays in seeking treatment. Survival rates from the disease are approximately 100 percent. Systemic drug therapy for melanoma mainly depends on the properties and stage at which melanoma is detected.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market players are adopting many strategies so as to attract the audience and to gain highest market share, these strategies can be listed as maintaining product uniqueness, offering attractive discounts, mergers with related organizations, alliances with different companies to increase sales area globally and others. Analyst at AMA Research estimates that United States Vendors will contribute the maximum growth to Global Melanoma Drugs market throughout the forecasted period. Established and emerging Vendors should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bristol-Myers Squibb (United States), Enzon Pharmaceuticals (United States), Exelixis (United States), GlaxoSmithKline (United Kingdom), Merck (United States), Pfizer (United States), Janssen Biotech (United States), Hoffmann-La Roche Ltd ( Switzerland), Navidea Biopharmaceuticals (United States) and AstraZeneca (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Vendors which are also part of the research coverage are Novartis (Switzerland), Ono Pharmaceutical (Japan), Amgen (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Melanoma Drugs market by , Application (Hospitals, Clinics and Other) and Region.



On the basis of geography, the market of Melanoma Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapy, the sub-segment i.e. Chemotherapy will boost the Melanoma Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Introduction of novel therapeutics with enhanced efficacy and Companies are undertaking various R&D activities to find new indications

Market Growth Drivers:
Exposure to ultraviolet (UV) light due to increasing global warming and Increment in the count of chronic diseases like melanoma, skin cancer, and skin allergies

Challenges:
Availability of other successful therapy

Restraints:
Lack of innovative medicine in this sector and Associated side effects of the drugs

Opportunities:
Rising skin diseases due to air pollution and Increasing number of FDA approvals

Market Leaders and their expansionary development strategies
In April 2023, Pfizer Inc., announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
In October 2023, Bristol Myers Squibb announced that Opdivo (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon the existing adjuvant indication for Opdivo and further reinforcing the company’s legacy of providing treatment options for melanoma patients.1 The approval is based on the Phase 3 CheckMate -76K trial, which compared Opdivo (n=526) to placebo (n=264).1,2


Key Target Audience
Manufacturer, Raw material supplier, Distributors/Traders/Wholesalers, Industry Association, Downstream Vendors, Governments and investment communities and Research organizations and associations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Other
By Therapy
  • Chemotherapy
  • Immuno-therapy
  • Targeted Therapy
  • Radiation Therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Exposure to ultraviolet (UV) light due to increasing global warming
      • 3.2.2. Increment in the count of chronic diseases like melanoma, skin cancer, and skin allergies
    • 3.3. Market Challenges
      • 3.3.1. Availability of other successful therapy
    • 3.4. Market Trends
      • 3.4.1. Introduction of novel therapeutics with enhanced efficacy
      • 3.4.2. Companies are undertaking various R&D activities to find new indications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Melanoma Drugs, by Application, Therapy and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Melanoma Drugs (Value)
      • 5.2.1. Global Melanoma Drugs by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Other
      • 5.2.2. Global Melanoma Drugs by: Therapy (Value)
        • 5.2.2.1. Chemotherapy
        • 5.2.2.2. Immuno-therapy
        • 5.2.2.3. Targeted Therapy
        • 5.2.2.4. Radiation Therapy
      • 5.2.3. Global Melanoma Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Melanoma Drugs (Price)
  • 6. Melanoma Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Enzon Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Exelixis (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Janssen Biotech (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hoffmann-La Roche Ltd ( Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Navidea Biopharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Melanoma Drugs Sale, by Application, Therapy and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Melanoma Drugs (Value)
      • 7.2.1. Global Melanoma Drugs by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Other
      • 7.2.2. Global Melanoma Drugs by: Therapy (Value)
        • 7.2.2.1. Chemotherapy
        • 7.2.2.2. Immuno-therapy
        • 7.2.2.3. Targeted Therapy
        • 7.2.2.4. Radiation Therapy
      • 7.2.3. Global Melanoma Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Melanoma Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Melanoma Drugs: by Application(USD Million)
  • Table 2. Melanoma Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 3. Melanoma Drugs Clinics , by Region USD Million (2018-2023)
  • Table 4. Melanoma Drugs Other , by Region USD Million (2018-2023)
  • Table 5. Melanoma Drugs: by Therapy(USD Million)
  • Table 6. Melanoma Drugs Chemotherapy , by Region USD Million (2018-2023)
  • Table 7. Melanoma Drugs Immuno-therapy , by Region USD Million (2018-2023)
  • Table 8. Melanoma Drugs Targeted Therapy , by Region USD Million (2018-2023)
  • Table 9. Melanoma Drugs Radiation Therapy , by Region USD Million (2018-2023)
  • Table 10. South America Melanoma Drugs, by Country USD Million (2018-2023)
  • Table 11. South America Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 12. South America Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 13. Brazil Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 14. Brazil Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 15. Argentina Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 16. Argentina Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 17. Rest of South America Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 18. Rest of South America Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 19. Asia Pacific Melanoma Drugs, by Country USD Million (2018-2023)
  • Table 20. Asia Pacific Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 21. Asia Pacific Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 22. China Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 23. China Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 24. Japan Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 25. Japan Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 26. India Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 27. India Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 28. South Korea Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 29. South Korea Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 30. Taiwan Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 31. Taiwan Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 32. Australia Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 33. Australia Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 36. Europe Melanoma Drugs, by Country USD Million (2018-2023)
  • Table 37. Europe Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 38. Europe Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 39. Germany Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 40. Germany Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 41. France Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 42. France Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 43. Italy Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 44. Italy Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 45. United Kingdom Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 46. United Kingdom Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 47. Netherlands Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 48. Netherlands Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 49. Rest of Europe Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 50. Rest of Europe Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 51. MEA Melanoma Drugs, by Country USD Million (2018-2023)
  • Table 52. MEA Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 53. MEA Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 54. Middle East Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 55. Middle East Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 56. Africa Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 57. Africa Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 58. North America Melanoma Drugs, by Country USD Million (2018-2023)
  • Table 59. North America Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 60. North America Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 61. United States Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 62. United States Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 63. Canada Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 64. Canada Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 65. Mexico Melanoma Drugs, by Application USD Million (2018-2023)
  • Table 66. Mexico Melanoma Drugs, by Therapy USD Million (2018-2023)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Melanoma Drugs: by Application(USD Million)
  • Table 78. Melanoma Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 79. Melanoma Drugs Clinics , by Region USD Million (2025-2030)
  • Table 80. Melanoma Drugs Other , by Region USD Million (2025-2030)
  • Table 81. Melanoma Drugs: by Therapy(USD Million)
  • Table 82. Melanoma Drugs Chemotherapy , by Region USD Million (2025-2030)
  • Table 83. Melanoma Drugs Immuno-therapy , by Region USD Million (2025-2030)
  • Table 84. Melanoma Drugs Targeted Therapy , by Region USD Million (2025-2030)
  • Table 85. Melanoma Drugs Radiation Therapy , by Region USD Million (2025-2030)
  • Table 86. South America Melanoma Drugs, by Country USD Million (2025-2030)
  • Table 87. South America Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 88. South America Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 89. Brazil Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 90. Brazil Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 91. Argentina Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 92. Argentina Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 93. Rest of South America Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 94. Rest of South America Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 95. Asia Pacific Melanoma Drugs, by Country USD Million (2025-2030)
  • Table 96. Asia Pacific Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 97. Asia Pacific Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 98. China Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 99. China Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 100. Japan Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 101. Japan Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 102. India Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 103. India Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 104. South Korea Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 105. South Korea Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 106. Taiwan Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 107. Taiwan Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 108. Australia Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 109. Australia Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 110. Rest of Asia-Pacific Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 111. Rest of Asia-Pacific Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 112. Europe Melanoma Drugs, by Country USD Million (2025-2030)
  • Table 113. Europe Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 114. Europe Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 115. Germany Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 116. Germany Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 117. France Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 118. France Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 119. Italy Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 120. Italy Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 121. United Kingdom Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 122. United Kingdom Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 123. Netherlands Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 124. Netherlands Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 125. Rest of Europe Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 126. Rest of Europe Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 127. MEA Melanoma Drugs, by Country USD Million (2025-2030)
  • Table 128. MEA Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 129. MEA Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 130. Middle East Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 131. Middle East Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 132. Africa Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 133. Africa Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 134. North America Melanoma Drugs, by Country USD Million (2025-2030)
  • Table 135. North America Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 136. North America Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 137. United States Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 138. United States Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 139. Canada Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 140. Canada Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 141. Mexico Melanoma Drugs, by Application USD Million (2025-2030)
  • Table 142. Mexico Melanoma Drugs, by Therapy USD Million (2025-2030)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Melanoma Drugs: by Application USD Million (2018-2023)
  • Figure 5. Global Melanoma Drugs: by Therapy USD Million (2018-2023)
  • Figure 6. South America Melanoma Drugs Share (%), by Country
  • Figure 7. Asia Pacific Melanoma Drugs Share (%), by Country
  • Figure 8. Europe Melanoma Drugs Share (%), by Country
  • Figure 9. MEA Melanoma Drugs Share (%), by Country
  • Figure 10. North America Melanoma Drugs Share (%), by Country
  • Figure 11. Global Melanoma Drugs share by Players 2023 (%)
  • Figure 12. Global Melanoma Drugs share by Players (Top 3) 2023(%)
  • Figure 13. Global Melanoma Drugs share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 16. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 17. Enzon Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Enzon Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 19. Exelixis (United States) Revenue, Net Income and Gross profit
  • Figure 20. Exelixis (United States) Revenue: by Geography 2023
  • Figure 21. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 23. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck (United States) Revenue: by Geography 2023
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2023
  • Figure 27. Janssen Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 28. Janssen Biotech (United States) Revenue: by Geography 2023
  • Figure 29. Hoffmann-La Roche Ltd ( Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Hoffmann-La Roche Ltd ( Switzerland) Revenue: by Geography 2023
  • Figure 31. Navidea Biopharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Navidea Biopharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 33. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Global Melanoma Drugs: by Application USD Million (2025-2030)
  • Figure 36. Global Melanoma Drugs: by Therapy USD Million (2025-2030)
  • Figure 37. South America Melanoma Drugs Share (%), by Country
  • Figure 38. Asia Pacific Melanoma Drugs Share (%), by Country
  • Figure 39. Europe Melanoma Drugs Share (%), by Country
  • Figure 40. MEA Melanoma Drugs Share (%), by Country
  • Figure 41. North America Melanoma Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb (United States)
  • Enzon Pharmaceuticals (United States)
  • Exelixis (United States)
  • GlaxoSmithKline (United Kingdom)
  • Merck (United States)
  • Pfizer (United States)
  • Janssen Biotech (United States)
  • Hoffmann-La Roche Ltd ( Switzerland)
  • Navidea Biopharmaceuticals (United States)
  • AstraZeneca (United Kingdom)
Additional players considered in the study are as follows:
Novartis (Switzerland) , Ono Pharmaceutical (Japan) , Amgen (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 222 Pages 84 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Melanoma Drugs Market Quantitative research analysis
Global Melanoma Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bristol-Myers Squibb (United States), Enzon Pharmaceuticals (United States), Exelixis (United States), GlaxoSmithKline (United Kingdom), Merck (United States), Pfizer (United States), Janssen Biotech (United States), Hoffmann-La Roche Ltd ( Switzerland), Navidea Biopharmaceuticals (United States) and AstraZeneca (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Introduction of novel therapeutics with enhanced efficacy " is seen as one of major influencing trends for Melanoma Drugs Market during projected period 2023-2030.
The Melanoma Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Melanoma Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Neuromyelitis Optica Drug Comprehensive Study by Type (Glucocorticoids, Immunoglobulin), Application (Acute Attack, Remission Prophylactic treatment), Product Type (Production Share, Price Rage, Cost...
$ 3500
Protein Therapeutic Comprehensive Study by Type (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), Application (Cancer, ...
$ 3750
Pet Ear Care Products Comprehensive Study by Type (Ear Cleansing Solution (Medicated, OTC (Over the Counter)), Ear Cleaner Wipes, Others), Application (Dogs, Cats, Others), Sales Channel (Online Sale...
$ 3500
Undegradable Protein Comprehensive Study by Type (Plant-based, Animal Based), Application (Aquaculture, Others), Distribution Channel (Online Sales Channel, Offline Sales Channel) Players and Region ...
$ 3500
Montelukast API Comprehensive Study by Type (Montelukast Sodium Amorphous, Montelukast Sodium Crystalline), Application (Asthma,, Allergic Rhinitis, Bronchospasm, Urticaria, Others), Dosage Form (Tab...
$ 3350
Drug & Pharmaceuticals & Cosmetics Retail Comprehensive Study by Type (Cosmetic, Pharmaceutical), Application (Child, Women, Men), Channel (Direct Sales, Distribution Channel) Players and Region - Gl...
$ 3400